Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer
Main finding · PFSResult — go to the resultHazard ratio 0.9 CI 0.54–1.5Authors' conclusion
Contrary to preclinical evidence, elevated FT4 levels do not affect PFS in patients with IR/HR-DTC.
Study context
- Population
- Patients with intermediate- and high-risk DTC treated with total thyroidectomy, RAI and TSH suppression therapy, with at least 3 TSH and free T4 (FT4) values; median age 46 (34–59) years, 64.1% women, median RAI dosage 159 (110–410) mCi739 screened
- Participants
- 382 patients
- Exposure
- Elevated FT4 vs non-elevated FT4
- Outcome
- PFS
- Follow-up
- 7.1 (3.4-12.7) years
Methodological detailsmulti-institutional, landmark analyses at 6, 12 and 18 months
- Multi-institutional
- Landmark analyses at 6, 12 and 18 months
Main finding
As reported in the abstract
Hazard ratio
0.9
CI 0.54–1.5
P = 0.69
Elevated FT4vs non-elevated FT4
HR 0.9 (CI 0.54–1.5); P = 0.69
- Disease progression during follow-up
- 34.6%
Observational data: associations, not effects.
Further findings
Factors associated with shorter progression-free survival (PFS)
| HR (CI) | P value | ||
|---|---|---|---|
| Age | 1.02 (1.004–1.04) | P = 0.01 | |
| Tumor size | 1.15 (1.04–1.28) | P = 0.01 | |
| Metastases to the lateral neck lymph nodes | 2.9 (1.7–4.74) | P < 0.001 | |
| Metastases to bones | 4.87 (1.79–13.3) | P = 0.002 | |
| Metastases to brain | 5.56 (2.54–12.2) | P < 0.001 | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer. J Clin Endocrinol Metab. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →